TABLE 3.
Multivariable Models for Prevalence of Cataract at Five Years after Initial Cancer Diagnosis and End of Follow-Up and Risk of Incident Cataract among Those Surviving Five Years or More
| Baseline characteristics | Prevalence at 5 years | |||||
|---|---|---|---|---|---|---|
| Cases | Percentage (%) |
OR | 95% CI | |||
| Age | Per 1 year | 200 | 1.4 | 0.99 | 0.96 | 1.02 |
| Sex | Male | 107 | 1.4 | 1 (ref.) | ||
| Female | 93 | 1.4 | 1.08 | 0.80 | 1.46 | |
| Type of first cancer | Bone sarcoma | 3 | 0.3 | 1 (ref.) | ||
| CNS | 15 | 0.9 | 0.75 | 0.21 | 2.73 | |
| HL | 2 | 0.1 | 0.26 | 0.04 | 1.72 | |
| Kidney (Wilms’) | 3 | 0.2 | 1.34 | 0.26 | 6.96 | |
| Leukemia | 112 | 2.4 | 6.61 | 1.98 | 22.02 | |
| NHL | 8 | 0.8 | 1.55 | 0.40 | 6.08 | |
| Neuroblastoma | 12 | 1.3 | 3.40 | 0.89 | 12.94 | |
| Soft tissue sarcoma | 45 | 3.8 | 3.37 | 0.98 | 11.57 | |
| Radiation dose to lens, Gy (mean) | <0.5 (0.03) | 35 | 0.4 | 1 (ref.) | ||
| 0.5–<1.5 (1.05) | 6 | 0.5 | 4.21 | 1.64 | 10.82 | |
| 1.5–<2.5 (2.09) | 7 | 0.4 | 0.59 | 0.26 | 1.35 | |
| 2.5–<3.5 (2.94) | 30 | 2.1 | 2.57 | 1.53 | 4.33 | |
| 3.5–<5.0 (4.30) | 8 | 2.2 | 7.01 | 3.16 | 15.53 | |
| 5.0–<10.0 (6.29) | 39 | 6.1 | 20.66 | 12.56 | 33.97 | |
| 10.0–<20.0 (13.26) | 26 | 15.2 | 26.76 | 15.20 | 47.10 | |
| 20–60 (41.02) | 36 | 35.6 | 140.48 | 74.71 | 264.15 | |
| EOR/Gy | 1.53 | 0.79 | 2.27 | |||
| Incidence follow-up ≥5 years | Prevalence at end of follow-up | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cases | IDa | HRb | 95% CI | Cases | Percentage (%) |
OR | 95% CI | ||
| 283 | 1.26 | 0.99 | 0.97 | 1.02 | 483 | 3.5 | 0.99 | 0.97 | 1.01 |
| 152 | 1.31 | 1 (ref.) | 259 | 1.9 | |||||
| 131 | 1.21 | 1.03 | 0.81 | 1.30 | 224 | 1.6 | 1.10 | 0.91 | 1.33 |
| 9 | 0.46 | 1 (ref.) | 12 | 1.0% | 1 (ref.) | ||||
| 33 | 1.36 | 1.00 | 0.46 | 2.20 | 48 | 2.9% | 0.78 | 0.39 | 1.53 |
| 27 | 0.81 | 1.02 | 0.46 | 2.28 | 29 | 1.5% | 1.00 | 0.48 | 2.07 |
| 4 | 0.18 | 0.41 | 0.12 | 1.35 | 7 | 0.6% | 0.63 | 0.24 | 1.64 |
| 163 | 2.23 | 2.38 | 1.15 | 4.90 | 275 | 5.8% | 3.18 | 1.70 | 5.95 |
| 24 | 1.37 | 1.76 | 0.80 | 3.87 | 32 | 3.0% | 1.73 | 0.86 | 3.45 |
| 8 | 0.50 | 0.89 | 0.33 | 2.40 | 20 | 2.1% | 1.47 | 0.68 | 3.16 |
| 15 | 0.78 | 0.99 | 0.42 | 2.32 | 60 | 5.1% | 1.66 | 0.84 | 3.27 |
| 70 | 0.54 | 1 (ref.) | 105 | 1.3 | 1 (ref.) | ||||
| 17 | 0.76 | 1.73 | 0.95 | 3.14 | 23 | 1.8 | 2.17 | 1.29 | 3.67 |
| 55 | 1.90 | 2.46 | 1.67 | 3.61 | 62 | 3.5 | 1.84 | 1.31 | 2.59 |
| 57 | 2.20 | 2.26 | 1.54 | 3.33 | 87 | 6.1 | 2.81 | 2.05 | 3.84 |
| 21 | 3.79 | 5.88 | 3.54 | 9.79 | 29 | 8.1 | 7.68 | 4.92 | 11.99 |
| 24 | 2.78 | 4.91 | 2.99 | 8.08 | 63 | 9.8 | 9.97 | 7.01 | 14.17 |
| 29 | 22.50 | 30.02 | 18.95 | 47.57 | 55 | 32.2 | 25.95 | 17.47 | 38.56 |
| 5 | 8.30 | 18.58 | 7.24 | 47.68 | 41 | 40.6 | 56.95 | 34.44 | 94.17 |
| 0.80 | 0.47 | 1.14 | 0.92 | 0.65 | 1.20 | ||||
Notes. OR = odds ratio; HR = hazard ratio; CI = confidence interval; CNS = central nervous system; HL=Hodgkin lymphoma; NHL=non-Hodgkin lymphoma; EOR = excess odds ratio.
a
Incidence density (ID) per 1,000 person-years.
b
Mutually adjusted for all variables.